Understanding and controlling amyloid aggregation with chirality

Curr Opin Chem Biol. 2021 Oct:64:1-9. doi: 10.1016/j.cbpa.2021.01.003. Epub 2021 Feb 18.

Abstract

Amyloid aggregation and human disease are inextricably linked. Examples include Alzheimer disease, Parkinson disease, and type II diabetes. While seminal advances on the mechanistic understanding of these diseases have been made over the last decades, controlling amyloid fibril formation still represents a challenge, and it is a subject of active research. In this regard, chiral modifications have increasingly been proved to offer a particularly well-suited approach toward accessing to previously unknown aggregation pathways and to provide with novel insights on the biological mechanisms of action of amyloidogenic peptides and proteins. Here, we summarize recent advances on how the use of mirror-image peptides/proteins and d-amino acid incorporations have helped modulate amyloid aggregation, offered new mechanistic tools to study cellular interactions, and allowed us to identify key positions within the peptide/protein sequence that influence amyloid fibril growth and toxicity.

Keywords: Amyloid; Chirality; Mirror-image peptides; Modulation of aggregation pathways.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Amino Acid Sequence
  • Amyloid beta-Peptides / chemistry
  • Amyloid beta-Peptides / metabolism
  • Amyloid* / chemistry
  • Diabetes Mellitus, Type 2*
  • Humans
  • Peptides / chemistry

Substances

  • Amyloid
  • Amyloid beta-Peptides
  • Peptides